Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Malvern, PA, US. The stock last traded at $17.15, up 9.80% on the session, giving a market capitalisation of $3.56B. On trailing twelve-month figures it carries a trailing P/E of 0.06, a net margin of 0.0%. Its beta of 2.60 implies it has historically moved more than the broad market.
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Galera Therapeutics, Inc. is most often compared with the following Healthcare names: